样式: 排序: IF: - GO 导出 标记为已读
-
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-19 Can Zhou, Fantian Zeng, Haijun Yang, Zeying Liang, Guanyu Xu, Xiao Li, Xingdang Liu, Jian Yang
-
Non-invasive assessment of stimulation-specific changes in cerebral glucose metabolism with functional PET Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-16 Godber Mathis Godbersen, Pia Falb, Sebastian Klug, Leo R. Silberbauer, Murray Bruce Reed, Lukas Nics, Marcus Hacker, Rupert Lanzenberger, Andreas Hahn
-
Early detection of anthracycline-induced cardiotoxicity using [68 Ga]Ga-FAPI-04 imaging Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-16
Abstract Purpose Anthracycline-induced cardiotoxicity (AIC), whose major manifestation is diffuse myocardial fibrosis, is an important clinical problem in cancer therapy. Therefore, early identification and treatment are clinically important. This study aims to explore the feasibility of using 68 Ga-labelled fibroblast activation protein (FAP) inhibitor ([68 Ga]Ga-FAPI) positron emission tomography/computed
-
Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-14 Luca Sofia, Federico Massa, Stefano Raffa, Matteo Pardini, Dario Arnaldi, Matteo Bauckneht, Silvia Morbelli
-
ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-14
Abstract Purpose The cluster of differentiation (CD70) is a potential biomarker of clear cell renal cell carcinoma (ccRCC). This study aims to develop CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging tracers and explore the diagnostic value in preclinical studies and the potential value in detecting metastases in ccRCC patients. Methods Four novel CD70-specific
-
[18F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-12 Jinbo Gui, Mengting Li, Jia Xu, Xiao Zhang, Heng Mei, Xiaoli Lan
-
[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-12 Swayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Chandrasekhar Bal
-
Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-08 Christos Sachpekidis, Olof Enqvist, Johannes Ulén, Annette Kopp-Schneider, Leyun Pan, Elias K. Mai, Marina Hajiyianni, Maximilian Merz, Marc S. Raab, Anna Jauch, Hartmut Goldschmidt, Lars Edenbrandt, Antonia Dimitrakopoulou-Strauss
-
Thoracic aortic microcalcification activity in combined positron emission tomography and magnetic resonance imaging Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-08 Jennifer Nash, Samuel Debono, Beth Whittington, Jakub Kaczynski, Tim Clark, Gillian Macnaught, Scott Semple, Edwin J R van Beek, Adriana Tavares, Damini Dey, Michelle C Williams, Piotr J Slomka, David E Newby, Marc R Dweck, Alexander J Fletcher
-
Guiding principles on the education and practice of theranostics Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-08 Thomas N. B. Pascual, Diana Paez, Andrei Iagaru, Gopi Gnanasegaran, Sze Ting Lee, Mike Sathekge, John M. Buatti, Francesco Giammarile, Akram Al-Ibraheem, Manuela Arevalo Pardo, Richard P. Baum, Berardino De Bari, Simona Ben-Haim, Jean-Yves Blay, Anita Brink, Enrique Estrada-Lobato, Stefano Fanti, Anja Tea Golubic, Jun Hatazawa, Ora Israel, Ana Kiess, Peter Knoll, Lizette Louw, Giuliano Mariani, Siroos
Purpose The recent development and approval of new diagnostic imaging and therapy approaches in the field of theranostics have revolutionised nuclear medicine practice. To ensure the provision of these new imaging and therapy approaches in a safe and high-quality manner, training of nuclear medicine physicians and qualified specialists is paramount. This is required for trainees who are learning theranostics
-
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-07 Julia Fricke, Frida Westerbergh, Lisa McDougall, Chiara Favaretto, Emanuel Christ, Guillaume P. Nicolas, Susanne Geistlich, Francesca Borgna, Melpomeni Fani, Peter Bernhardt, Nicholas P. van der Meulen, Cristina Müller, Roger Schibli, Damian Wild
-
Preoperative evaluation of mediastinal lymph nodes in non-small cell lung cancer using [68Ga]FAPI-46 PET/CT: a prospective pilot study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-07
Abstract Purpose Mediastinal nodal staging is crucial for surgical candidate selection in non-small cell lung cancer (NSCLC), but conventional imaging has limitations often necessitating invasive staging. We investigated the additive clinical value of fibroblast activation protein inhibitor (FAPI) PET/CT, an imaging technique targeting fibroblast activation protein, for mediastinal nodal staging of
-
Preclinical validation of a novel brain-penetrant PET ligand for visualization of histone deacetylase 6: a potential imaging target for neurodegenerative diseases Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-05 Tetsuro Tago, Muneyuki Sakata, Masakatsu Kanazawa, Shigeyuki Yamamoto, Kenji Ishii, Jun Toyohara
-
Tau aggregation following subcortical hemorrhage Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-04 Elena Jaeger, Gérard N. Bischof, Oezguer A. Onur, Marc Schlamann, Alexander Drzezga
-
Dose–effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-19
Abstract Purpose Aim of this study was to investigate a dose-response relationship, dose-toxicity relationship, progression free survival (PFS) and overall survival (OS) in neuroendocrine tumour liver metastases (NELM) treated with holmium-166-microspheres radioembolization ([166Ho]-radioembolization). Materials and methods Single center, retrospective study included patients with NELM that received
-
Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-19 Wenjia Zhang, Xiaolong Liang, Xinyu Zhang, Wei Tong, Guangyuan Shi, Haozhuo Guo, Zhengyu Jin, Jie Tian, Yang Du, Huadan Xue
-
Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-17 Christian Ferschmann, Konstantin Messerschmidt, Johannes Gnörich, Henryk Barthel, Ken Marek, Carla Palleis, Sabrina Katzdobler, Anna Stockbauer, Urban Fietzek, Anika Finze, Gloria Biechele, Jost-Julian Rumpf, Dorothee Saur, Matthias L. Schroeter, Michael Rullmann, Leonie Beyer, Florian Eckenweber, Stephan Wall, Andreas Schildan, Marianne Patt, Andrew Stephens, Joseph Classen, Peter Bartenstein, John
-
EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-17 Caroline Stokke, Silvano Gnesin, Johannes Tran-Gia, Francesco Cicone, Søren Holm, Marta Cremonesi, Johan Blakkisrud, Thomas Wendler, Nic Gillings, Ken Herrmann, Felix M. Mottaghy, Jonathan Gear
-
Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-15 Matteo Cotta Ramusino, Federico Massa, Cristina Festari, Federica Gandolfo, Valentina Nicolosi, Stefania Orini, Flavio Nobili, Giovanni B. Frisoni, Silvia Morbelli, Valentina Garibotto
-
Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-15 Zhoulei Li, Zhihui Chen, Ruonan Zhang, Jinjiang Lin, Siyun Huang, Kuangyu Shi, Xiaodi Shen, Zijun Xiang, Xinyue Wang, Lili Huang, Qingzhu Zheng, Xubin Liu, Jinyu Tan, Minhu Chen, Ziping Li, Ren Mao, Xiangsong Zhang, Yangdi Wang, Xinming Song, Xuehua Li
-
Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin’s lymphoma Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-14 Mikhail Ya. Yadgarov, M. M. Dunaykin, G. I. Shestopalov, C. Kailash, E. D. Kireeva, N. V. Myakova, Yu. N. Likar
-
90Y post-radioembolization clinical assessment with whole-body Biograph Vision Quadra PET/CT: image quality, tumor, liver and lung dosimetry Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-13 Konstantinos G. Zeimpekis, Lorenzo Mercolli, Maurizio Conti, Hasan Sari, Axel Rominger, Hendrik Rathke
-
Incorporating the [68Ga]Ga-PSMA PET/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-12 Levent Kabasakal, Ruştu Turkay, Bulent Onal
-
Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-10 Meixi Liu, Yuejuan Cheng, Chunmei Bai, Hong Zhao, Ru Jia, Jingci Chen, Wenjia Zhu, Li Huo
-
A patient journey audit tool (PJAT) to assess quality indicators in a nuclear medicine service Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-10
Abstract Purpose To develop a nuclear medicine specific patient journey audit tool (PJAT) to survey and audit patient journeys in a nuclear medicine department such as staff interaction with patients, equipment, quality of imaging and laboratory procedures, patient protection, infection control and radiation safety, with a view to optimising patient care and providing a high-quality nuclear medicine
-
Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial) Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-08 Pim Hendriks, Daphne D. D. Rietbergen, Arian R. van Erkel, Minneke J. Coenraad, Mark J. Arntz, Roel J. Bennink, Andries E. Braat, Stijn Crobach, Otto M. van Delden, Petra Dibbets-Schneider, Tom van der Hulle, Heinz-Josef Klümpen, Rutger W. van der Meer, J. Frank W. Nijsen, Catharina S. P. van Rijswijk, Joey Roosen, Bastian N. Ruijter, Frits Smit, Mette K. Stam, R. Bart Takkenberg, Maarten E. Tushuizen
-
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-08 Fereshteh Yousefirizi, Ivan S. Klyuzhin, Joo Hyun O, Sara Harsini, Xin Tie, Isaac Shiri, Muheon Shin, Changhee Lee, Steve Y. Cho, Tyler J. Bradshaw, Habib Zaidi, François Bénard, Laurie H. Sehn, Kerry J. Savage, Christian Steidl, Carlos F. Uribe, Arman Rahmim
-
Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-08 Lifang Liu, Jiawei Zhong, Ziqi Zhang, Xiaoting Ye, Xinlu Wang, Shaoyu Liu, Zhanwen Zhang
-
Preclinical evaluation of 68 Ga-labeled peptide CK2 for PET imaging of NRP-1 expression in vivo Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-06 Qingzhu Liu, Shuyue Cai, Jiacong Ye, Quan Xie, Rongbin Liu, Ling Qiu, Jianguo Lin
-
Guardians of precision: advancing radiation protection, safety, and quality systems in nuclear medicine Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-06 Francesco Giammarile, Peter Knoll, Jolanta Kunikowska, Diana Paez, Enrique Estrada Lobato, Miriam Mikhail-Lette, Richard Wahl, Ola Holmberg, May Abdel-Wahab, Andrew M. Scott, Roberto C. Delgado Bolton
Background In the rapidly evolving field of nuclear medicine, the paramount importance of radiation protection, safety, and quality systems cannot be overstated. This document provides a comprehensive analysis of the intricate regulatory frameworks and guidelines, meticulously crafted and updated by national and international regulatory bodies to ensure the utmost safety and efficiency in the practice
-
Radioiodine versus radiofrequency ablation to treat autonomously functioning thyroid nodules: a systematic review and comparative meta-analysis Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-02 Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček
-
Head-to-head comparison between [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-01 Qiao He, Zhengkun Zhang, Linqi Zhang, Bing Zhang, Yali Long, Yuying Zhang, Zhihong Liao, Zhihao Zha, Xiangsong Zhang
-
Correction to: Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-22 Thu Hang Lai, Barbara Wenzel, Sladjana Dukić-Stefanović, Rodrigo Teodoro, Lucie Arnaud, Aurélie Maisonial-Besset, Valérie Weber, Rareş-Petru Moldovan, Sebastian Meister, Jens Pietzsch, Klaus Kopka, Tareq A. Juratli, Winnie Deuther-Conrad, Magali Toussaint
-
The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-17
Abstract Purpose [18F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the
-
Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-17 Artem Chaban, Birgit Waschulzik, Denise Bernhardt, Claire Delbridge, Friederike Schmidt-Graf, Arthur Wagner, Benedikt Wiestler, Wolfgang Weber, Igor Yakushev
-
Impact of patient motion on parametric PET imaging Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-15 Alessia Artesani, Joyce van Sluis, Johannes H. van Snick, Laura Providência, Walter Noordzij, Charalampos Tsoumpas
-
A systematic review for the evidence of recommendations and guidelines in hybrid nuclear cardiovascular imaging Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-15 Florent L. Besson, Giorgio Treglia, Jan Bucerius, Constantinos Anagnostopoulos, Ronny R. Buechel, Marc R. Dweck, Paula A. Erba, Oliver Gaemperli, Alessia Gimelli, Olivier Gheysens, Andor W. J. M. Glaudemans, Gilbert Habib, Fabian Hyafil, Mark Lubberink, Christopher Rischpler, Antti Saraste, Riemer H. J. A. Slart
-
New EAU/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-13
Abstract Introduction The European Association of Urology (EAU) and the American Society of Clinical Oncology (ASCO) recently issued updated guidelines on penile cancer, emphasising dynamic sentinel node biopsy (DSNB) as the preferred method for surgical staging among patients with invasive penile tumours and no palpable inguinal lymphadenopathy. This paper outlines the rationale behind this new recommendation
-
First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 Affibody Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-13 Mingru Zhang, Fei Kang, Tong Xing, Junling Wang, Taoqi Ma, Guiyu Li, Zhiyong Quan, Weidong Yang, Xiaoyuan Chen, Jing Wang
-
First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-12
Abstract Purpose This is a first-in-human study to evaluate the radiation dosimetry of a new prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, [18F]AlF-P16-093, and also initial investigation of its ability to detect PSMA-positive tumors using PET scans in a cohort of prostate cancer (PCa) patients. Methods The [18F]AlF-P16-093 was automatically synthesized with a GE TRACERlab
-
Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-11 Jisu Kim, Seunghwan Lee, Dongwoo Kim, Hyun Jeong Kim, Kyeong Taek Oh, Sun Jung Kim, Young Deuk Choi, Frederik L. Giesel, Klaus Kopka, Alexander Hoepping, Misu Lee, Mijin Yun
-
Surgical evidence-based comparison of [68Ga]Ga-FAPI-04 PET and MRI-DWI for assisting debulking surgery in ovarian cancer patients Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-10
Abstract Purpose Imaging assessment of abdominopelvic tumor burden is crucial for debulking surgery decision in ovarian cancer patients. This study aims to compare the efficiency of [68Ga]Ga-FAPI-04 FAPI PET and MRI-DWI in the preoperative evaluation and its potential impact to debulking surgery decision. Methods Thirty-six patients with suspected/confirmed ovarian cancer were enrolled and underwent
-
Impact on cardiovascular outcome of coronary revascularization-induced changes in ischemic perfusion defect and myocardial flow reserve Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-09 Roberta Assante, Emilia Zampella, Adriana D’Antonio, Teresa Mannarino, Valeria Gaudieri, Carmela Nappi, Parthiban Arumugam, Mariarosaria Panico, Pietro Buongiorno, Mario Petretta, Alberto Cuocolo, Wanda Acampa
-
A bis-boron boramino acid PET tracer for brain tumor diagnosis Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-09 Zhu Li, Junyi Chen, Ziren Kong, Yixin Shi, Mengxin Xu, Bo-Shuai Mu, Nan Li, Wenbin Ma, Zhi Yang, Yu Wang, Zhibo Liu
-
Surgical radioguidance with beta-emitting radionuclides; challenges and possibilities: A position paper by the EANM Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-08 Pedro Fragoso Costa, Kuangyu Shi, Soren Holm, Sergi Vidal-Sicart, Tereza Kracmerova, Giovanni Tosi, Jan Grimm, Dimitris Visvikis, Wolfram H. Knapp, Gopinath Gnanasegaran, Fijs W. B. van Leeuwen
-
Platelet-derived growth factor receptor β-targeted positron emission tomography imaging for the noninvasive monitoring of liver fibrosis Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-08
Abstract Purpose Noninvasive quantifying activated hepatic stellate cells (aHSCs) by molecular imaging is helpful for assessing disease progression and therapeutic responses of liver fibrosis. Our purpose is to develop platelet-derived growth factor receptor β (PDGFRβ)-targeted radioactive tracer for assessing liver fibrosis by positron emission tomography (PET) imaging of aHSCs. Methods Comparative
-
[18F]SynVesT-1 and [18F]FDG quantitative PET imaging in the presurgical evaluation of MRI-negative children with focal cortical dysplasia type II Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-06 Ling Xiao, Jinhui Yang, Haoyue Zhu, Ming Zhou, Jian Li, Dingyang Liu, Yongxiang Tang, Li Feng, Shuo Hu
-
A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [18F]flortaucipir PET in a memory clinic cohort Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-06
Abstract Purpose [18F]Flortaucipir PET is a powerful diagnostic and prognostic tool for Alzheimer’s disease (AD). Tau status definition is mainly based in the literature on semi-quantitative measures while in clinical settings visual assessment is usually preferred. We compared visual assessment with established semi-quantitative measures to classify subjects and predict the risk of cognitive decline
-
Nuclear imaging in the new ESC Guidelines: the age of maturity Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-02 Paola Anna Erba, Maria Nazarena Pizzi, Albert Roque, Riemer H. J. A. Slart
-
MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-29 Carlos Huesa-Berral, Julia D. Withrow, Robert J. Dawson, Chris Beekman, Wesley E. Bolch, Harald Paganetti, Eric Wehrenberg-Klee, Alejandro Bertolet
-
2-[18F]FDG PET-based quantification of lymph node metabolic heterogeneity for predicting lymph node metastasis in patients with colorectal cancer Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-27 Lian Xu, Gan Huang, Yining Wang, Gang Huang, Jianjun Liu, Ruohua Chen
-
Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-23 Qi Yang, Zhao Chen, Yongkang Qiu, Wenpeng Huang, Tianyao Wang, Lele Song, Xinyao Sun, Cuicui Li, Xiaojie Xu, Lei Kang
-
Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [18F]FDG-PET/MRI Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-22 Kai Jannusch, Frederic Dietzel, Nils Martin Bruckmann, Janna Morawitz, Matthias Boschheidgen, Peter Minko, Ann-Kathrin Bittner, Svjetlana Mohrmann, Harald H. Quick, Ken Herrmann, Lale Umutlu, Gerald Antoch, Christian Rubbert, Julian Kirchner, Julian Caspers
-
Automated identification of uncertain cases in deep learning-based classification of dopamine transporter SPECT to improve clinical utility and acceptance Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-22 Thomas Budenkotte, Ivayla Apostolova, Roland Opfer, Julia Krüger, Susanne Klutmann, Ralph Buchert
-
Effects of medication on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-20 Yuliya Piatkova, Matthieu Doyen, Sébastien Heyer, Ayaz Tahmazov, Solene Frismand, Lucie Hopes, Laetitia Imbert, Antoine Verger
-
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-20 Conrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, Jan-Michel Heger, Beatrice Casadei, Laura Beckmann, Ken Herrmann, Franziska J. Dekorsy, Nadine Kutsch, Peter Borchmann, Stefano Fanti, Wolfgang G. Kunz, Marion Subklewe, Carsten Kobe, Pier Luigi Zinzani, Matthias Stelljes, Katrin S. Roth, Alexander Drzezga, Richard Noppeney, Kambiz Rahbar, H. Christian Reinhardt, Bastian von Tresckow, Robert
-
Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-20
Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. 68Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, 18F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale
-
Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-19
Abstract Purpose In our study, our aim was to investigate the role of [68 Ga]Ga-PSMA-11 PET /CT imaging in the diagnosis of clinically significant prostate cancer (csPCa) (ISUP GG 2 and higher) in patients initially diagnosed with ISUP GG 1 and 2 after prostate biopsy. Materials and methods We retrospectively reviewed 147 patient records in whom [68 Ga]Ga-PSMA-11 PET/CT imaging was performed preoperatively
-
Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive l-[methyl-11C] methionine cohort study with two PET scanners Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-19 Weiyan Zhou, Jianbo Wen, Qi Huang, Yan Zeng, Zhirui Zhou, Yuhua Zhu, Lei Chen, Yihui Guan, Fang Xie, Dongxiao Zhuang, Tao Hua
-
Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2023-12-18
Abstract Purpose Current treatments for osteosarcoma (OS) have a poor prognosis, particularly for patients with metastasis and recurrence, underscoring an urgent need for new targeted therapies to improve survival. Targeted alpha-particle therapy selectively delivers cytotoxic payloads to tumors with radiolabeled molecules that recognize tumor-associated antigens. We have recently demonstrated the